Novartis Pharmaceuticals

SEP 4, 2026 · PHASE 1 TRIAL

Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

ClinicalTrials.gov

This is a Phase 1 safety and tolerability study in early recruitment with no results posted; it is designed to evaluate dose-limiting toxicities and adverse events, not efficacy.

SEP 4, 2026 · PHASE 1/2 TRIAL

A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.

ClinicalTrials.gov

This is a Phase I/II trial registration with no posted results; it is actively enrolling to establish safety, tolerability, and preliminary efficacy in a novel radiopharmaceutical combination.

SEP 4, 2026 · PHASE 1 TRIAL

Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer

ClinicalTrials.gov

Phase 1 safety and tolerability study in advanced NSCLC with actual enrollment of 41 participants; no efficacy results reported in this registry record.

AUG 20, 2026 · PHASE 1 TRIAL

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

ClinicalTrials.gov

Phase 1 dose-escalation study with safety endpoints only; no efficacy results reported in registry record. Designed to establish recommended dose of [177Lu]Lu-NeoB in combination therapy.

AUG 20, 2026 · PHASE 2 TRIAL

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

ClinicalTrials.gov

This is an active Phase 2 trial registration with no results reported; it describes a planned study of asciminib in pediatric Ph+ CML, a population lacking established efficacy and safety data.

AUG 19, 2026 · SAFETY RECALL

Class II recall: Diovan (valsartan) 160 mg, 90 tablets, Rx only, Manufactured by: Patheon Manufacturing Services LLC, Greenville, NC 27834, Distributed by: Novartis Pharmaceutic

U.S. Food and Drug Administration

FDA Class II recall of valsartan 160 mg due to failed dissolution specifications; affects product quality and bioavailability but does not report clinical trial outcomes.

AUG 18, 2026 · PHASE 1/2 TRIAL

Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

ClinicalTrials.gov

This is a rollover/access study with no reported efficacy results; it documents continued treatment in benefiting participants and ongoing safety monitoring in Phase 1/2 populations.

AUG 18, 2026 · PHASE 3 TRIAL

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

ClinicalTrials.gov

This is a trial registration with no posted results; the study is actively recruiting and outcome data are not yet available for assessment.